Iovance Biotherapeutics, Inc. (FRA:2LB)
2.166
-0.102 (-4.50%)
At close: Jan 30, 2026
Iovance Biotherapeutics Revenue
Iovance Biotherapeutics had revenue of $67.46M USD in the quarter ending September 30, 2025, with 15.20% growth. This brings the company's revenue in the last twelve months to $250.43M, up 175.62% year-over-year. In the year 2024, Iovance Biotherapeutics had annual revenue of $164.07M with 13,698.99% growth.
Revenue (ttm)
$250.43M
Revenue Growth
+175.62%
P/S Ratio
3.99
Revenue / Employee
$298.84K
Employees
838
Market Cap
852.03M EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 164.07M | 162.88M | 13,698.99% |
| Dec 31, 2023 | 1.19M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Gelsenwasser AG | 3.36B |
| Paul Hartmann AG | 2.44B |
| FRoSTA Aktiengesellschaft | 652.00M |
| tonies SE | 510.38M |
| Maschinenfabrik Berthold Hermle AG | 469.42M |
| Südwestdeutsche Salzwerke AG | 347.96M |
| EUROKAI GmbH & Co. KGaA | 262.47M |
| Northern Data AG | 200.27M |